Association between circulatory complement activation and hypertensive renal damage: a case–control study

References

• Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021;398(10302):786–802. doi: 10.1016/S0140-6736(21)00519-5.
   PubMed Web of Science ®Google Scholar
• Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol. 2011;7(1):11–21. doi: 10.1038/nrneph.2010.154.
   PubMed Web of Science ®Google Scholar
• Appel LJ, Wright JT, Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168(8):832–839. doi: 10.1001/archinte.168.8.832.
   PubMedGoogle Scholar
• Pascual JM, Rodilla E, Costa JA, et al. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension. 2014;64(6):1228–1234. doi: 10.1161/HYPERTENSIONAHA.114.04273.
   PubMed Web of Science ®Google Scholar
• Harwani SC, Ratcliff J, Sutterwala FS, et al. Nicotine mediates CD161a + renal macrophage infiltration and premature hypertension in the spontaneously hypertensive rat. Circ Res. 2016;119(10):1101–1115. doi: 10.1161/CIRCRESAHA.116.309402.
   PubMed Web of Science ®Google Scholar
• Wu Y, An C, Jin X, et al. Disruption of CXCR6 ameliorates kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension. Sci Rep. 2020;10(1):133. doi: 10.1038/s41598-019-56933-7.
   PubMed Web of Science ®Google Scholar
• Harboe M, Ulvund G, Vien L, et al. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138(3):439–446. doi: 10.1111/j.1365-2249.2004.02627.x.
   PubMed Web of Science ®Google Scholar
• Harboe M, Garred P, Karlstrøm E, et al. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol. 2009;47(2-3):373–380. doi: 10.1016/j.molimm.2009.09.005.
   PubMed Web of Science ®Google Scholar
• Chen XH, Ruan CC, Ge Q, et al. Deficiency of complement C3a and C5a receptors prevents angiotensin II-induced hypertension via regulatory T cells. Circ Res. 2018;122(7):970–983. doi: 10.1161/CIRCRESAHA.117.312153.
   PubMed Web of Science ®Google Scholar
• Engström G, Hedblad B, Berglund G, et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens. 2007;21(4):276–282. doi: 10.1038/sj.jhh.1002129.
   PubMed Web of Science ®Google Scholar
• Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens (Greenwich). 2008;10(9):677–683. doi: 10.1111/j.1751-7176.2008.00002.x.
   PubMed Web of Science ®Google Scholar
• Coan PM, Barrier M, Alfazema N, et al. Complement factor B is a determinant of both metabolic and cardiovascular features of metabolic syndrome. Hypertension. 2017;70(3):624–633. Published online July 24, doi: 10.1161/HYPERTENSIONAHA.117.09242.
   PubMed Web of Science ®Google Scholar
• Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, et al. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria [published correction appears in Sci Rep. 2018 Mar 2;8(1):4154]. Sci Rep. 2017;8(1):4154. doi: 10.1038/s41598-017-09042-2.
   Google Scholar
• Shagdarsuren E, Wellner M, Braesen JH, et al. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97(7):716–724. doi: 10.1161/01.RES.0000182677.89816.38.
   PubMed Web of Science ®Google Scholar
• Chaona Y, Ying Z, Yuan L, et al. Role of excessive activation of the complement bypass pathway in malignant hypertensive nephrosclerosis. Chinese J Nephrol. 2020;36 (01):18–25. doi: 10.3760/cma.j.issn.1001-7097.2020.01.004.
   PubMedGoogle Scholar
• Békássy ZD, Kristoffersson AC, Rebetz J, et al. Aliskiren inhibits renin-mediated complement activation. Kidney Int. 2018;94(4):689–700. doi: 10.1016/j.kint.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Plasse RA, Nee R, Olson SW. Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome. Clin Kidney J. 2019;13(1):39–41. doi: 10.1093/ckj/sfz146.
   PubMed Web of Science ®Google Scholar
• Kopp A, Hebecker M, Svobodová E, et al. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules. 2012;2(1):46–75. doi: 10.3390/biom2010046.
   PubMedGoogle Scholar
• Timmermans S, Abdul-Hamid MA, Vanderlocht J, et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int. 2017;91(6):1420–1425. doi: 10.1016/j.kint.2016.12.009.
   PubMed Web of Science ®Google Scholar
• Alsenz J, Schulz TF, Lambris JD, et al. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J. 1985;232(3):841–850. doi: 10.1042/bj2320841.
   PubMed Web of Science ®Google Scholar
• Cotran RS, Rennke HG. Anionic sites and the mechanisms of proteinuria. N Engl J Med. 1983;309(17):1050–1052. doi: 10.1056/NEJM198310273091709.
   PubMed Web of Science ®Google Scholar
• Groggel GC, Stevenson J, Hovingh P, et al. Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int. 1988;33(2):517–523. doi: 10.1038/ki.1988.28.
   PubMed Web of Science ®Google Scholar
• Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes. 1987;36(3):374–381. doi: 10.2337/diab.36.3.374.
   PubMed Web of Science ®Google Scholar
• Mahan JD, Sisson-Ross S, Vernier RL. Glomerular basement membrane anionic charge site changes early in aminonucleoside nephrosis. Am J Pathol. 1986;125(2):393–401.
   PubMed Web of Science ®Google Scholar
• Perkins SJ, Fung KW, Khan S. Molecular Interactions between Complement Factor H and Its Heparin and Heparan Sulfate Ligands. Front Immunol. 2014;5:126. doi: 10.3389/fimmu.2014.00126.
   PubMed Web of Science ®Google Scholar
• Borza DB. Glomerular basement membrane heparan sulfate in health and disease: a regulator of local complement activation. Matrix Biol. 2017;57-58:299–310. doi: 10.1016/j.matbio.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Brinkkoetter PT, Holtgrefe S, van der Woude FJ, et al. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol. 2004;15(1):33–40. doi: 10.1097/01.ASN.0000102476.50041.44.
   PubMed Web of Science ®Google Scholar
• Kramer A, van den Hoven M, Rops A, et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol. 2006;17(9):2513–2520. doi: 10.1681/ASN.2006020184.
   PubMed Web of Science ®Google Scholar
• van den Hoven MJ, Waanders F, Rops AL, et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant. 2009;24(9):2637–2645. doi: 10.1093/ndt/gfp182.
   PubMed Web of Science ®Google Scholar
• Heintz B, Stöcker G, Mrowka C, et al. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension. Hypertension. 1995;25(3):399–407. doi: 10.1161/01.HYP.25.3.399.
   PubMed Web of Science ®Google Scholar